The details are included in B12 Supplementation Trials, but the baseline parameters were such outliers, and the response to treatment was so drastic, that the lines didnt fit in the charts
Semaglutide produces nausea in approximately 20-25% of patients compared to 25-30% for tirzepatide, though individual variation is substantial
Cognitive or affective benefits are more evident in individuals with higher inflammatory or metabolic burden, whereas studies involving low-risk participants or short follow-up durations often report minimal effects (165, 208)
It is not intended for human consumption, therapeutic use, veterinary use, cosmetic use, or diagnostic applications
Usually, patients feel fewer hunger pangs and consequently eat far less